Combivir

Combivir

Combivir is the brand name for a combination of drugs lamivudine and zidovudine used to treat Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV). These drugs act as antiretroviral agents and fight against HIV by competitively inhibiting and reducing the activity of reverse transcriptase. It was initially approved in 1997 by the U.S. Food and Drug Administration. Combivir is gaining prominence in the market owing to the increasing prevalence of HIV diagnosis and treatment due to unprotected coitus, sharing of contaminated needles or syringes, absence of awareness about the mode of transmission of HIV. For instance, in 2021, according to the Pan African Medical Journal’s report of HIV on antiretroviral therapy in public hospitals of Kembata Tembaro Zone, Southern Ethiopia, the prevalence of unprotected sex was (40.9%) among which there were 49.4% of females and 31.5% of males. Several factors, including a surge in the increasing government awareness programs regarding the mode of transmission of HIV and available treatment options for HIV, rising demand for oral drugs, rising drug addiction rate, and increased investments from the government, public, and private sectors in healthcare departments are driving the growth of the market during the forecast period. According to the National Center for Drug Abuse Statistics, half of people 12 and older have used illicit drugs at least once and the federal budget for drug control in 2020 was USD 35 billion.

The Combivir Market is expected to grow at a steady rate of around 3% owing to the increased investment in research & development globally by pharmaceutical companies due to the surge in AIDS cases which needs to be controlled. For instance, according to U.S. HIV.gov, in 2021, there were 32,100 estimated new HIV infections in the U.S. Many new therapies are being introduced for treating this deadly retrovirus. Several other factors, such as the introduction of generic drugs and their cost-effectiveness, and government initiatives are also driving this market of combivir at a steady rate. For instance, the U.S.-based Department of Health and Human Services (HHS) initiated a program the ' Ending the HIV Epidemic (EHE)’ in 2019 with an ambitious goal of reducing all new HIV infections in the U.S. by 90% by 2030. HHS has also provided multiple funding opportunities to jurisdictions, including simultaneous investments in sexually transmitted diseases specialty clinics.

• Based on type, the market is bifurcated into branded and generic. The branded segment held the maximum share in the global market of combivir in 2022. This segment dominated the market because of their good brand reputation . This draws a maximum number of consumers towards branded drugs. Hence, due to the above reasons, the branded segment held a significant share of the market in 2022.
• Based on application, the market is bifurcated into nonoccupational exposure and occupational exposure. The occupational exposure segment is expected to hold a significant share of the market in the forecast period owing to the increased number of casualties in healthcare centers owing to workload, long working hours, and time pressure. For instance, a commercial intelligence company Definitive Healthcare published a report in 2022 saying an estimated 333,000 healthcare providers left their jobs in 2021, due to burnout, long hours, and heavy patient loads. Apart from this, the rising number of cases of drug addiction is boosting the patient load in hospitals and is also impelling the growth of this segment. Hence, amongst applications, the occupational exposure category is expected to witness higher CAGR during the forecast period.
• For a better understanding of the market adoption of combivir, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America dominated the global combivir market in the year 2022 due to the increasing HIV cases, increasing drug addiction, and rising number of investments in developing effective therapeutics. Government organizations are initiating AIDS awareness programs to provide efficient care to patients. For instance, the U.S.-based National HIV/AIDS Strategy for 2022-2025 aims to educate all its citizens regarding HIV/AIDS including HIV transmission, prevention, and behaviors that place individuals at greatest risk for infection. Thus, North America held a significant share of the market in the year 2022.
• Some of the major players operating in the market include Mylan Inc.; Macleods Pharmaceuticals Ltd.; Lupin; Aurobindo Pharma; Pfizer Inc.; Cipla Inc.; ViiV Healthcare group of companies; Hetero; Strides Pharma Science Limited; GSK plc.